2'-deoxy-2-fluoroadenosine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 447864 |
| CHEMBL ID | 1229920 |
| CHEBI ID | 39723 |
| SCHEMBL ID | 976990 |
| MeSH ID | M0368266 |
| Synonym |
|---|
| CHEMBL1229920 , |
| 5-(6-amino-2-fluoro-purin-9-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol |
| 21679-12-9 |
| nsc-114093 |
| 2-fluoro-2'-deoxyadenosine, 96% |
| 1Z34 |
| DB02947 |
| 2-fluoro-2'-deoxyadenosine |
| 2FD , |
| CHEBI:39723 , |
| 2'-deoxy-2-fluoroadenosine |
| (2r,3s,5r)-5-(6-amino-2-fluoropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol |
| bdbm50370376 |
| adenosine,2'-deoxy-2-fluoro- |
| ZWPYUXAXLRFWQC-KVQBGUIXSA-N |
| 2-fluoro-2'deoxyadenosine |
| SCHEMBL976990 |
| J-014232 |
| A900767 |
| Q27120370 |
| (2r,3s,5r)-5-(6-amino-2-fluoro-9h-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol |
| 2t63dt4kwu , |
| (2r,3s,5r)-5-(6-amino-2-fluoro-9h-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol |
| 2-fluorodeoxyadenosine |
| unii-2t63dt4kwu |
| (9-(2-deoxy-b-d-ribofuranosyl)-2-fluoroadenine |
| PD059748 |
| Class | Description |
|---|---|
| adenosines | Any purine ribonucleoside that is a derivative of adenosine. |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, purine nucleoside phosphorylase | Trichomonas vaginalis | IC50 (µMol) | 420.0000 | 420.0000 | 420.0000 | 420.0000 | AID977608 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID44000 | Compound was tested for cytotoxicity against CCRF-CEM cell lines | 1992 | Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2 | Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. |
| AID34585 | Compound was evaluated for inhibition of adenylate cyclase from rat brain | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Synthesis of 2',5'-dideoxy-2-fluoroadenosine and 2',5'-dideoxy-2,5'-difluoroadenosine: potent P-site inhibitors of adenylyl cyclase. |
| AID81745 | Compound was tested for cytotoxicity against HEp-2 cell lines | 1992 | Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2 | Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. |
| AID96710 | Compound was tested for cytotoxicity against L1210 cell lines | 1992 | Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2 | Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2005 | The Journal of biological chemistry, Jun-10, Volume: 280, Issue:23 | Identification of a subversive substrate of Trichomonas vaginalis purine nucleoside phosphorylase and the crystal structure of the enzyme-substrate complex. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2005 | The Journal of biological chemistry, Jun-10, Volume: 280, Issue:23 | Identification of a subversive substrate of Trichomonas vaginalis purine nucleoside phosphorylase and the crystal structure of the enzyme-substrate complex. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||